The basic pharmacokinetic parameters of MTX administered as monotherapy as well as in the combined therapy with simultaneous and prior administation of fU were investigated . The parameters were determined in the two-compartment open system on the basis of measurement of MTX levels in mice after i.p. administration of a single dose 20 mg/ kg of the drug. The FU dose was 20 mg/kg, too. The effect of the circadian rhythm on the kinetics of MTX have been taken into consideration. In one series of experiments the drugs were administered in the morning and in the other during midday hours . The statistical analysis of the obtained results showed the essential effect of the administration time on the pharmacokinetic parameters of MTX in mice . The statistical significal differences could be found: C max, AUC, CL, T o.;;. The differences in T o . . , parameter resulting from coadministration of FU with the same circadian rhythm of MTX administration have b een observed.
Introduction
Methotrexate (MTX) and are administered together in the treatment of some neoplastic diseases such as advanced stage carcinomas of the alimentary tract or breast cancer. In spite of the fact that such combination chemotherapy has now been in use for several years, experimental ( 1 ) as well as clinical studies ( 2, 3) are still carried out in order to explain the interaction occuring between these two drugs and to obtain a better therapeutic effect in the treat- § Abbreviations: MTX or M -methotrexate, MTX(Glu )npolyglutaminate of methotrexate, FU or F -5-fluorouracil, M Fs-methotrexate plus 5 -fluorouracil simultaneously, F2M-5 -tluorouracil 2h prior to methotrexate , FdUMP -5-Huorodeoxyuridine monophosphate. ment of humans . MTX and FU, despite different essential mechanisms of activity, may compete for the utilization of endogenous folates (4) . Additionally, MTX in the form of polyglutaminate derivatives binds to thymidylate synthetase, the site of action of one of the active FU metabolites, FdUMP, forming a triple complex: thymidylate synthetase, FdUMP, MTX (Glu)n ( 5).
In view of the above, the timing of administration of the drugs and the interval b e tween their administration, may influence the ultimate therapeutic effect.
The experimental studies of MTX and fU interactions in vivo were carried out at various times in different centres using mice inoculated with various neoplasms ( 6, 7). However, the available literature doc s not include any papers conPtcridines / Vol. 7 / No . 3 ccrning the effect of FU on the pharmacokinetics of MTX in mice .
In the presented study basic pharmacokinetic parameters have been determined for MTX used in monotherapy as well as in combination chemotherapy with simultaneous and prior administration of FU. The effects of the circadian rhythm on the kinetics of MTX have been taken into consideration. In one series of experiments the drugs were administered in the morning and in the other during midday hours.
Materials and Methods

Animals
The experiments were carried out on 60 male mice of BDFI strain, obtained from the Polish Academy of Science (Wrocw), weighing 20-25 g, aged 10 weeks. The animals were held in quarantine for 14 days after arrival and fed with standard laboratory diet and water ad libitum .
Therapeutics
MTX (Lederle ) and FU (Farmitalia) were administered intraperitoneally both at 20 mg/kg doses. The solutions were prepared just before injections so as to obtain for the used doses injection volumes of 0 ,1 mljl0 g b. w. In the first series of experiments MTX was administered at 07:00, in the second one -at 13:00 hr. In both series the animals were divided into Lhree groups. Group one was injected with MTX (MTX schedule), group two -with MTX immediately followed by FU (MFs schedule) and group threewith FU 2h prior to the administration of MTX.
Determination of blood serum level of MTX in mice
After the administration of the drug/ drugs, the blood for MTX determinations was collected with a microsyringe from the orbital sinus at 5 , 10, 15, 30, 45, 60, 90 and 120 min. after MTX injection. Methotrexate level was determined according to the FPIA method, using a kit and a TD. apparatus manufactured by Abbott.
Determination of pharmacokinetic parameters of MTX
The pharmacokinetic parameters of MTX were determined on the basis of the open bicompartmental kinetic mode l. The following val ues w ere L.lkulated: -maximum blood senlm concentration of the drug -area under the curve in 0 -2h time -area under the curve in 0-= h time -volume of distribution -direction coefficient of the rapid phase -direction coefficient of elimination -total body clearance -elimination half-time
Statistical analysis
The differences of pharmacokinetic parameter values for MTX among the groups were calculated using Student -t test with the level of significance set at p < 0,05.
Results and Interpretation
The values of pharmacikinetic parameters obtained for MTX in monotherapy and in combination chemotherapy with FU have been presented in Table 1 ,
The obtained results indicate that there is an influence of the physiological circadian rhythm on the kinetics of MTX intraperitoneally administered to mice, both in monotherapy MTX schedule and in combination with FU -administered simultaneously (MFs schedule) and prior to the injection of MTX (F2M schedule).
As far as absorption after intraperitoneal injection is concerned, the influence can be seen on the obtained values of mean maximum concentration -Cmax, which are significantly higher after MTX administration at 13:00 than after the administration of the drug at 07 :00 hr. Areas under the concentration curves in time: AUC o2 and AUC o . oo are significantly higher after MTX administration at 13:00 hr. Significant differences in the rapid phase of drug distribution in the organism, dependent on the time of MTX administration, have been observed.
'The values of the direction coefficient a for the rapid phase are significantly higher after MTX administration at 13:00 whereas its administration in the morning leads to faster elimination of the drug from the mouse organism. It is reflected by the higher value of the direction coefficient P for the elimination curve and by faster clearance of the drug, The biological half-life period -t o ,5 is shorter after MTX administration at 0 7:00 than the value obtained after the administration of the drug at 13:00 hr.
The changes in the values of kinetic parameters (significant at 13:00 only) and between the calculated clearance values -CL (significant at 07:00 only), after simultaneous MTX and fU administration than after MTX monotherapy, No differences in MTX kinetics after combination chemotherapy involving administration of FU prior to MTX (F2M schedule) at 07:00 have been observed in comparison with MTX monotherapy.
However, after the administration of the drugs according to this schedule during midday hours, MTX at 13:00 and FU 2h earlier -the following statistically significant differences in the values of kinetic parameters for MTX have been observed in comparison with monotherapy: a lower value of direction coefficient ex, a higher value of direction coefficient f3, shorter biological half-life period -to,s, For the obtained em", values no statistically significant diseases have been demonstrated, but C m" value is reduced by 30% as compared with that obtained in MTX monotherapy, administered at 13:00 hr. No statistically significant differences in the values of kinetic parameters have been demonstrated between the two combination treatment schedules -MFs and f2M tor the same time of MTX administration in the morning and after midday MTX administration in kinetic parameters.
Discussion
The investigation of interactions between newlysynthesized compounds as well as the elucidation of interactions occuring among the drugs already used, utilizing experimental neoplasms in the in vivo model, have had a well-established position in experimental oncology. In comparison with in vitro studies, they allow tor obtaining the response of the whole organism to the applied therapy (8 ) .
The presented study of the blood serum levels of MTX in mice and the determination of pharmacokinetic parameters of MTX after single intraperitoneal administration in monotherapy, as well as in combination chemotherapy with FU, involving either simultaneous administration of MTX and FU, or FU administartion prior to MTX, have demonstrated, first of all, the influence of the circadian rhythm on the kinetics of MTX. However, the changes resulting from FU administration have also been observed in comparison with MTX monotherapy. These changes are more pronounced after midday administration, when the biological activity of mice decreases than after combination chemotherapy administered in the morning.
It should be mentioned that 07:00 has been selected on the basis of the paper Song et al. (9) .
The authors of that paper did not demonstrate any significant changes in the kinetics of MTX in mice after administration of the drug at 07:00 and 1 :00 corresponds with the peak of biological activity in mice. The results obtained at 07:00 may be to some extent a counterpart of the changes which would be obtained if the experiments were carried out during the night.
Among the available literature, only one paper has been found which quotes the selected kinetic parameters of MTX in mice after therapy with this drug (8) . The authors, however, do not give the time of MTX administration. The values of C max = 25,5 !-lg/m and AUC = 19,4 f.1g/m x hr after the administration of MTX at the 25 mg/kg dose presented by them are similar to these obtained in the present study, but only for midday administration of MTX.
Song et al. presented in their paper the pharmacokinetic parameters of MTX after the administration of a toxic dose -100 mg/kg. The drug was administered at various times of the day. The changes in kinetic parameters of MTX dependent on the time of administration were demonstrated (9). The reports discussing the effects of sequence of MTX and FU administration and the interval between the drugs on the obtained biochemical and therapeutic results were received very enthusiastically. Attempts were made to apply the findings in the treatment of humans.
On the basis of the presented own results it seems necessary to take into account that the selected intervals between MTX and FU administration may cause different rapidity of kinetic changes of the drugs when they are administered at difterent times of day and night. Not only the Pteridincs / Vol. 7 / No. 3
Graczyk: Chronopharmacokinetics of methotrexate in mice biochemical interaction between MTX and FU, discussed widely by numerous papers, takes place, but also the pharmacokinetic interaction, whose interpretation is more difficult if chronopharmacokinetic of the drugs is not taken into consideration. The more rapid elimination of MTX observed after simultaneous, and earlier, administration of FU, may explain at least partially the antagonism in the activity of these two drugs, observed in the course of the previous studies (7, 11) .
For the comparability of the obtained results of experiments, particularly those carried out on laboratory animals such as mice or rats, the exact times of drug injections should be stated. The application of the obtained results in clinical practice absolutely must take into consideration the fact, that the physiological circadian rhythm is different in laboratory animals and in humans. The activity of these animals, and consequently, the higher intensity of metabolism, take place at different times of the day than in man.
In the presented study a short interval (2h) between MTX and FU administration has been selected, as well as a low dose of FU . . It may be anticipated that higher FU doses as well as different, longer intervals bet\veen MTX and FU administration might have a more intensive influence on the obtained results concerning the kinetic values obtained for MTX. This, however, requires confirmation and appropriate 111-vestiga tion.
